Two Proteins Predict Poorer Outcome in Male Breast Cancer, Study Reports

Two Proteins Predict Poorer Outcome in Male Breast Cancer, Study Reports
The proteins eIF4E and eIF5 are involved in male breast cancer (MBC), and are biomarkers of a poorer disease prognosis, according to researchers at the University of Leeds in England. The study, “A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer,” was published in Clinical Cancer Research. Most people see breast cancer as a disease that affects women, but men can also develop it, although at a much lower incidence. Standard care for women and men with breast cancer is the same. But studies have indicated that MBC has different underling genetics and protein expression than breast cancer in women. This suggests that therapies for treating women may not be the best for treating men. In an attempt to identify differences between male and female breast cancer, researchers compared the expression levels of several proteins in samples collected from male and female breast cancer patients. They found eIF4E and eIF5 overexpressed in MBC samples. An evaluation of nearly 700 MBC samples confirmed the initial finding. "We screened breast tumors from hundreds of men to find out if their tumors expressed these proteins, and we found that a significant proportion of the men we tested had higher levels of these proteins,” Matt Humphries, the lead author of the study, said in a press release. Importantly, t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.